The decision to file is a result of the 14,000 claims the company faces in U.S. courts that allege Imerys’ talc causes ovarian cancer or mesothelioma, according to the court filings.
Under Chapter 11 of the U.S Bankruptcy Code, Imerys Talc can set up a trust to deal with the current talc cases and any future claims brought against the company. It will also bring the lawsuits under a single judge and allow Imerys to pressure plaintiffs for lower settlements.
“After carefully evaluating all possible options, we determined pursuing Chapter 11 protection is the best course of action to address our historic talc-related liabilities and position the companies for continued growth,” Giorgio La Motta, president of Imerys Talc America, told Bloomberg.
The talc unit, a subsidiary of Imerys SA, filed for bankruptcy protection in a Delaware.
Read the full report here.
More articles on pharmacy:
Better pharmacy access sought for rural Colorado residents
Following its rival, Sanofi and Regeneron slash price of cholesterol drug by 60%
Mount Carmel’s chief pharmacy officer out amid overprescribing scandal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
